AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
Authors
Keywords
Melanoma, Aurora A kinase, Targeted therapy, Combined therapy, 3D-human skin reconstruction model
Journal
Journal of Translational Medicine
Volume 12, Issue 1, Pages -
Publisher
Springer Nature
Online
2014-07-30
DOI
10.1186/s12967-014-0216-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The role of MEK inhibitors in the treatment of metastatic melanoma
- (2014) Antonio M. Grimaldi et al. CURRENT OPINION IN ONCOLOGY
- Analysis of the BRAF V600E mutation in primary cutaneous melanoma
- (2014) J.S.S. Inumaru et al. GENETICS AND MOLECULAR RESEARCH
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
- (2014) Grant A McArthur et al. LANCET ONCOLOGY
- BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAF V600E metastatic melanoma
- (2013) J S Wilmott et al. BRITISH JOURNAL OF CANCER
- Activities of multiple cancer-related pathways are associated withBRAFmutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells
- (2013) Dingxie Liu et al. CELL CYCLE
- Treatment of BRAF-Mutant Melanoma: The Role of Vemurafenib and Other Therapies
- (2013) S Jang et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors
- (2013) Karen E. Sheppard et al. EUROPEAN JOURNAL OF CANCER
- Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
- (2013) Paolo A. Ascierto et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma
- (2013) Kerstin Trunzer et al. JOURNAL OF CLINICAL ONCOLOGY
- TGF-β1 exposure induces epithelial to mesenchymal transition both in CSCs and non-CSCs of the A549 cell line, leading to an increase of migration ability in the CD133+ A549 cell fraction
- (2013) V Tirino et al. Cell Death & Disease
- Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
- (2013) H. Shi et al. Cancer Discovery
- The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
- (2013) E. M. Van Allen et al. Cancer Discovery
- Aurora A kinase (AURKA) in normal and pathological cell division
- (2012) Anna S. Nikonova et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence
- (2012) Yan Liu et al. EMBO Molecular Medicine
- BRAF/NRASMutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
- (2012) Maria Colombino et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With MetastaticBRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
- (2012) Kevin B. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- MAP kinase signaling and inhibition in melanoma
- (2012) R J Sullivan et al. ONCOGENE
- Translationale Forschung und Diagnostik beim Melanom
- (2012) J. Rüschoff et al. PATHOLOGE
- Comparative Analysis of Dynamic Cell Viability, Migration and Invasion Assessments by Novel Real-Time Technology and Classic Endpoint Assays
- (2012) Ridha Limame et al. PLoS One
- Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma
- (2011) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epithelial to Mesenchymal Transition by TGFβ-1 Induction Increases Stemness Characteristics in Primary Non Small Cell Lung Cancer Cell Line
- (2011) Giuseppe Pirozzi et al. PLoS One
- Cancer Statistics, 2009
- (2009) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Expression of Aurora A (but Not Aurora B) Is Predictive of Survival in Breast Cancer
- (2008) Y. Nadler et al. CLINICAL CANCER RESEARCH
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- (2008) J. Tsai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started